On Monday, Shares of Alibaba Group Holding Limited (NYSE:BABA), lost -3.14% to $62.60, after Barron’s slammed Alibaba Group Holding in an article published on Saturday entitled, “Alibaba: Why It Could Fall 50% Further.” Recently, Alibaba counter-punched. The stock market sided with the publication all day as shares closed Monday’s trading session down 3.14% to $62.60 on heavy trading volume.
The publication cited several problems that may be causing the stock to continue downward, counting growing competition in e-commerce from rivals like JD.com (JD) and a slowdown of China’s economy, as this could put a further dent in consumer spending.
In addition, Alibaba last week lowered its growth merchandise volume (GMV) forecasts for the second quarter, Barron’s noted.
Alibaba Group Holding Limited, through its auxiliaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally. It operates Taobao Marketplace, an online shopping destination; Tmall, a third-party platform for brands and retailers; Juhuasuan, a group buying marketplace; Alibaba.com, an online wholesale marketplace; Alitrip, an online travel booking platform; 1688.com, an online wholesale marketplace; and AliExpress, a consumer marketplace.
Shares of AbbVie Inc. (NYSE:ABBV), declined -0.69% to $58.94, during its last trading session.
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $0.51 per share.
The cash dividend is payable Nov. 14, 2015 to stockholders of record at the close of business on Oct. 15, 2015.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Shares of The Interpublic Group of Companies, Inc. (NYSE:IPG), inclined 0.71% to $19.80, during its last trading session.
Amtrak unveiled a new nationwide brand campaign “500 Destinations. Infinite Stories.” inspired by passengers’ travel experiences from across the U.S. The new campaign is designed to create top-of-mind awareness and showcases the comfort, freedom, service and value of train travel.
The storytelling at the heart of the campaign focuses on the unique experiences and adventures only rail travel can provide. Whether it’s a trip to college, a business trip with colleagues, a girls’ weekend, or a dream vacation across the country, Amtrak takes you there. From downtown to downtown, community to community, Amtrak connects passengers to more than 500 destinations, offering a smarter way to travel.
The new brand campaign also builds upon the value Amtrak offers to millions of passengers every year: a chance to relax and stretch out, move about freely and work or play.
The Interpublic Group of Companies, Inc. provides advertising and marketing services. The company operates in two segments, Integrated Agency Networks and Constituency Administration Group. It offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines.
Finally, Opko Health, Inc. (NYSE:OPK), ended its last trade with -0.59% loss, and closed at $10.03.
OPKO Health, declared that the U.S. Food and Drug Administration (FDA) has approved VARUBI™ (rolapitant) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, counting, but not limited to, highly emetogenic chemotherapy.
“We are extremely happy that our partners at TESARO were able to successfully develop and obtain FDA approval for VARUBI. TESARO’s excellent administration team is the ideal partner to successfully commercialize and reach VARUBI’s full commercial potential,” commented Phillip Frost, MD, OPKO’s Chairman and Chief Executive Officer.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
